{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:01:30Z","timestamp":1784808090583,"version":"3.55.0"},"reference-count":44,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd016370","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:06:52Z","timestamp":1784804812000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nucleic acid-based therapies for people with cystic fibrosis"],"prefix":"10.1002","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4207-4409","authenticated-orcid":false,"given":"Charlotte","family":"Addy","sequence":"additional","affiliation":[{"name":"All Wales Adult Cystic Fibrosis Centre; Cardiff and Vale University Health Board; Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9468-0268","authenticated-orcid":false,"given":"Nikolas","family":"Johl","sequence":"additional","affiliation":[{"name":"All Wales Adult Cystic Fibrosis Centre; Cardiff and Vale University Health Board; Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1514-2840","authenticated-orcid":false,"given":"Andrew P","family":"Prayle","sequence":"additional","affiliation":[{"name":"School of Medicine and NIHR Biomedical Research Centre; University of Nottingham; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7836-0151","authenticated-orcid":false,"given":"Nikki","family":"Jahnke","sequence":"additional","affiliation":[{"name":"Academic Unit of Lifespan and Population Health, Medicine & Health Sciences; University of Nottingham; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4143-5364","authenticated-orcid":false,"given":"Sherie","family":"Smith","sequence":"additional","affiliation":[{"name":"Academic Unit of Lifespan and Population Health, Medicine & Health Sciences; University of Nottingham; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Cochrane Cystic Fibrosis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD016370-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/humu.10041","article-title":"Cystic fibrosis: a worldwide analysis of CFTR mutations - correlation with incidence data and application to screening","volume":"19","author":"Bobadilla","year":"2002","journal-title":"Human Mutation"},{"issue":"4922","key":"10.1002\/14651858.CD016370-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene - cloning and characterization of complementary","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"issue":"3","key":"10.1002\/14651858.CD016370-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/adc.76.3.278","article-title":"Delta F508 in cystic fibrosis: willing but not able","volume":"76","author":"Southern","year":"1997","journal-title":"Archives of Disease in Childhood"},{"issue":"6","key":"10.1002\/14651858.CD016370-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1378\/chest.10-2077","article-title":"Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment","volume":"139","author":"Rogan","year":"2011","journal-title":"Chest"},{"key":"10.1002\/14651858.CD016370-BIB0005|cit5","unstructured":"Cystic Fibrosis Centre at the Hospital for Sick Children in Toronto Cystic fibrosis mutation database www.genet.sickkids.on.ca\/app"},{"issue":"5","key":"10.1002\/14651858.CD016370-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1046\/j.1469-1809.2003.00028.x","article-title":"The phenotypic consequences of CFTR mutations","volume":"67","author":"Rowntree","year":"2003","journal-title":"Annals of Human Genetics"},{"issue":"3","key":"10.1002\/14651858.CD016370-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000102068","article-title":"Cystic fibrosis and formes frustes of CFTR-related disease","volume":"74","author":"Southern","year":"2007","journal-title":"Respiration: International Review of Thoracic Diseases"},{"issue":"10408","key":"10.1002\/14651858.CD016370-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/S0140-6736(23)01608-2","article-title":"The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches","volume":"402","author":"Graeber","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD016370-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/arm92040026","article-title":"Cystic fibrosis: understanding cystic fibrosis transmembrane regulator mutation classification and modulator therapies","volume":"92","author":"Anwar","year":"2024","journal-title":"Advances in Respiratory Medicine"},{"issue":"11","key":"10.1002\/14651858.CD016370-BIB0010|cit10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010966.pub4","article-title":"Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)","author":"Heneghan","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD016370-BIB0011|cit11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009841.pub3","article-title":"Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis","author":"Skilton","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD016370-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"2501783","DOI":"10.1183\/13993003.01783-2025","article-title":"Advances in cystic fibrosis: CFTR modulator triple combinations","volume":"67","author":"Burgel","year":"2026","journal-title":"European Respiratory Journal"},{"issue":"12","key":"10.1002\/14651858.CD016370-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/S2213-2600(25)00206-1","article-title":"Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trials","volume":"13","author":"Mayer-Hamblett","year":"2025","journal-title":"Lancet Respiratory Medicine"},{"issue":"12","key":"10.1002\/14651858.CD016370-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1164\/rccm.202402-0389CI","article-title":"Lentiviral gene therapy for cystic fibrosis: a promising approach and first-in-human trial","volume":"210","author":"Davies","year":"2024","journal-title":"American Journal of Respiratory Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD016370-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.jcf.2023.04.008","article-title":"Inhaled mRNA therapy for treatment of cystic fibrosis: interim results of a randomized, double-blind, placebo-controlled phase 1\/2 clinical study","volume":"22","author":"Rowe","year":"2023","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD016370-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"175346662412978","DOI":"10.1177\/17534666241297877","article-title":"Modulator-refractory cystic fibrosis: defining the scope and challenges of an emerging at-risk population","volume":"18","author":"Somerville","year":"2024","journal-title":"Therapeutic Advances in Respiratory Disease"},{"issue":"3","key":"10.1002\/14651858.CD016370-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jcf.2022.12.007","article-title":"Lived experiences of people with cystic fibrosis that were not eligible for elexacaftor-tezacaftor-ivacaftor (ETI): A qualitative study","volume":"22","author":"Milo","year":"2023","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD016370-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/ppul.25859","article-title":"A survey: understanding the health and perspectives of people with CF not benefiting from CFTR modulators","volume":"57","author":"Kramer-Golinkoff","year":"2022","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD016370-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"2401898","DOI":"10.1183\/13993003.01898-2024","article-title":"Until it's done for everyone: the role of CFTR modulator label expansion","volume":"64","author":"Britto","year":"2024","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD016370-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respiratory Medicine"},{"issue":"8","key":"10.1002\/14651858.CD016370-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/thorax-2023-220100","article-title":"A refresh of the top 10 research priorities in cystic fibrosis","volume":"78","author":"Rowbotham","year":"2023","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD016370-BIB0022|cit22","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016370-BIB0023|cit23","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological expectations of Cochrane intervention reviews. Cochrane: London, Version August 2023 Available from https:\/\/community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD016370-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016370-BIB0025|cit25","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"issue":"6","key":"10.1002\/14651858.CD016370-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"key":"10.1002\/14651858.CD016370-BIB0027|cit27","unstructured":"Covidence Veritas Health Innovation 2026"},{"key":"10.1002\/14651858.CD016370-BIB0028|cit28","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2026"},{"key":"10.1002\/14651858.CD016370-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016370-BIB0030|cit30","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016370-BIB0031|cit31","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect (chapter last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016370-BIB0032|cit32","unstructured":"Deeks JJ Higgins JP Altman DG McKenzie JE Veroniki AA Chapter 10: Analysing data and undertaking meta-analyses (chapter last updated November 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"issue":"24","key":"10.1002\/14651858.CD016370-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"11","key":"10.1002\/14651858.CD016370-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1002\/sim.1303","article-title":"Aggregate data meta-analysis with time-to-event outcomes","volume":"21","author":"Williamson","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD016370-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016370-BIB0036|cit36","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing evidence in a meta-analysis (chapter last updated August 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"issue":"414","key":"10.1002\/14651858.CD016370-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016370-BIB0038|cit38","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence (chapter last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016370-BIB0039|cit39","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions (last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016370-BIB0040|cit40","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"},{"issue":"3","key":"10.1002\/14651858.CD016370-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jcf.2024.05.007","article-title":"Standards for the care of people with cystic fibrosis (CF); planning for a longer life","volume":"23","author":"Gramegna","year":"2024","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD016370-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"issue":"6","key":"10.1002\/14651858.CD016370-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/ppul.26954","article-title":"International disparities in diagnosis and treatment access for cystic fibrosis","volume":"59","author":"Guo","year":"2024","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD016370-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1163391","DOI":"10.3389\/fphar.2023.1163391","article-title":"Real-world disparities and ethical considerations with access to CFTR modulator drugs: mind the gap!","volume":"14","author":"Zampoli","year":"2023","journal-title":"Frontiers in Pharmacology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:06:59Z","timestamp":1784804819000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD016370"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":44,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd016370","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]}}}